---
type: "Symbol"
title: "Zymeworks (ZYME.US) — Community Discussions"
description: "Community discussions about this stock, including analyst opinions, earnings analysis, and investment strategies from verified financial professionals and active investors."
locale: "en"
url: "https://longbridge.com/en/quote/ZYME.US/topics.md"
symbol: "ZYME.US"
parent: "https://longbridge.com/en/quote/ZYME.US.md"
count: 9
datetime: "2026-03-14T06:15:45.859Z"
locales:
  - [en](https://longbridge.com/en/quote/ZYME.US/topics.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ZYME.US/topics.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ZYME.US/topics.md)
---

# Zymeworks (ZYME.US) — Community Discussions

### [Watching the market today, stable stocks like Miri…](https://longbridge.com/en/topics/38172237.md)

- Author: [浪漫照进现实](https://longbridge.com/en/profiles/7200440.md)
- Datetime: 2026-01-28T08:44:52.000Z
- Comments: 0
- Watching the market today, stable stocks like Mirion are just dragging their feet, with target prices fluctuating up and down but not much movement—holding them is a bit boring.Zymeworks, on the other

### [$Zymeworks(ZYME.US) Bosses, should we exit or keep…](https://longbridge.com/en/topics/36565291.md)

- Author: [青山 柯南](https://longbridge.com/en/profiles/16229597.md)
- Datetime: 2025-11-20T14:56:19.000Z
- Comments: 0
- $Zymeworks(ZYME.US) Bosses, should we exit or keep holding? 😄

### [Olema (OLMA.US) dropped another 3%+ with a turnove…](https://longbridge.com/en/topics/36554151.md)

- Author: [万里晴空ZVuE](https://longbridge.com/en/profiles/2833742.md)
- Datetime: 2025-11-20T09:08:21.000Z
- Comments: 0
- Olema (OLMA.US) dropped another 3%+ with a turnover rate of over 20% today. Feels like short-term capital is farming dungeons again? I checked the sector recently—anyone else paying attention?One inte

### [Damn🌚](https://longbridge.com/en/topics/36446675.md)

- Author: [Space X](https://longbridge.com/en/profiles/18192450.md)
- Datetime: 2025-11-17T18:33:32.000Z
- Comments: 1
- Damn🌚

**Comments:**

- **自来也 · 2025-11-24T21:48:34.000Z**: It's this

### [$Zymeworks(ZYME.US) It should be your turn tonight…](https://longbridge.com/en/topics/36429705.md)

- Author: [青山 柯南](https://longbridge.com/en/profiles/16229597.md)
- Datetime: 2025-11-17T12:44:01.000Z
- Comments: 5
- $Zymeworks(ZYME.US) It should be your turn tonight🤔️

**Comments:**

- **股涨 · 2025-11-17T13:07:50.000Z**: Got stuck again
- **vincent123 · 2025-11-17T12:50:39.000Z**: Meme stocks, be careful

### [Phase II clinical trial: Zanidatamab combined with palbociclib and fulvestrant is safe and effective in treating breast cancer](https://longbridge.com/en/topics/29504558.md)

- Author: [济无咎](https://longbridge.com/en/profiles/9874868.md)
- Datetime: 2025-05-11T10:08:35.000Z
- Comments: 0
- Zanidatamab was initially developed by $Zymeworks(ZYME.US). In 2018, $BEONE MEDICINES(06160.HK) $Beigene(BGNE.US) obtained the development and commercialization rights for Zanidatamab in the Asia-Paci

### [一条优于双抗、ADC 的赛道？海外先驱受挫，国内几家药企笑了](https://longbridge.com/en/topics/3467215.md)

- Author: [药械Talks](https://longbridge.com/en/profiles/6059509.md)
- Datetime: 2022-09-25T13:28:51.000Z
- Comments: 0
- 近期，美股上市公司 Zymeworks 因在研的 HER2 双抗 ADC 新药 ZW49 治疗实体瘤的 I 期临床数据不达预期，导致股价发生暴跌。ZW49 在临床 I 期阶段便遭遇挫折，无疑给其他在研双抗 ADC 药物带来了压力。更何况，双抗 ADC 为新兴技术，目前尚处于摸索验证阶段，最终能否成药仍有待验证。因此，究竟哪款在研药物能打破藩篱、成为全球首款获批上市的双抗 ADC 产品...

### [双抗研发 “竞速赛”，谁能抢得先机？](https://longbridge.com/en/topics/1286817.md)

- Author: [药械Talks](https://longbridge.com/en/profiles/6059509.md)
- Datetime: 2021-11-05T13:16:41.000Z
- Comments: 0
- 古罗马诗人奥维德曾言：“一匹马如果没有另一匹马紧紧追赶并要超过它，就永远不会疾驰飞奔。” 这就是竞争的重要性。在 PD-1 单抗内卷、差异化竞争策略的刺激下，双抗已经成为研发热门赛道。随着国内双抗药物研发即将迎来收获期，究竟谁能在这场 “竞速赛” 中抢得先机？让我们一睹为快。 一、全球仅有 4 款双抗药物上市如果说，PD-1 单抗开启了肿瘤免疫治疗 1.0 时代。那么...

### [Puma Biotechnology (PBYI) 坠地的天使](https://longbridge.com/en/topics/828859.md)

- Author: [锐璞生物](https://longbridge.com/en/profiles/4330866.md)
- Datetime: 2021-05-26T01:29:58.000Z
- Comments: 4
- $Puma BioTech(PBYI.US) 彪马生物也曾有过极其辉煌的过去，2012 年到 2014 年也曾有过一口气涨幅接近 2000% 的壮举。11/19/2020 更新：公司这个季度 N 药产品收益将近$50，产品成本 + 销售 + 研发开销$62.9, 但是公司现金数量基本没有怎么变化，比较神奇。PBYI 跟 CLVS 很类似，但是烧钱比$Clovis 肿瘤药物.US CLVS 要少很多

**Comments:**

- **二虎马斯克 · 2021-05-26T02:49:06.000Z**: 是啊 pbyi 明星股，印象中几年前一夜翻几倍，但其实 her2 治愈率从 85% 提到 90%，当时就觉得没啥价值。没想到跌这么多
- **二虎马斯克 · 2021-05-26T02:03:32.000Z**: 分析的很好，同意作者结论，没有投资价值。

## References

- [Zymeworks (ZYME.US)](https://longbridge.com/en/quote/ZYME.US.md)


> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/ZYME.US/topics.md) | [繁體中文](https://longbridge.com/zh-HK/quote/ZYME.US/topics.md)